PONTANEOUS epileptiform discharges within the amygdala and hippocampus 1 in temporal lobe epilepsy are the most common surgically remediable cause of seizures. These discharges are believed to originate in a circumscribed population of hyperexcitable neurons known as the epileptic focus. 6, 18 Resection of this epileptogenic tissue is an established approach to treat refractory epilepsy. In the past few years the increasing sophistication of preoperative localization of areas of epileptogenesis has increased confidence in resective epilepsy surgery. Nevertheless, rates of morbidity and patient acceptance would be improved by less invasive and more precisely targeted surgical methods. Focal application of neuronal toxins to specific cell populations, provided by using convection-enhanced delivery, represents an alternative to resection. As a first step toward evaluating the potential of such a chemical neurosurgical approach in the treatment of focal epilepsy, we examined the ability of the neurotoxin ibotenate to ameliorate seizure activity in a rat model of focal epilepsy.
Because of its ability to create axon-sparing excitotoxic lesions that destroy neurons in the vicinity of the injection site and spare fibers of passage, ibotenate has been extensively used as a neurotoxin in anatomical, neurochemical, and behavioral studies.
11 Unlike other excitatory neurotoxins, ibotenate does not create lesions remote from the site of injection and it is not epileptogenic. 8, 9 We examined whether administration of ibotenate can suppress electrical and behavioral seizure activity in the kainate epilepsy model. Kainate is a powerful convulsant that, similar to ibotenate, is a glutamate receptor agonist. Unlike ibotenate, however, kainate does not interact with NMDA receptors. Intraamygdala administration of kainate causes an acute episode of status epilepticus that lasts 1 or 2 days followed by a silent phase that extends over 1 to 3 weeks. Many kainate-treated animals exhibit spiking activity in amygdala EEG recordings and spontaneous recurrent behavioral seizures. 3 Our results indicate that ibotenate infusion can largely obliterate a kainate-induced seizure focus.
Materials and Methods
Male Sprague-Dawley rats, each weighing between 290 and 400 g, were obtained from the NIH animal program. All procedures were conducted in strict compliance with the NIH Guide for Care and Use of Laboratory Animals under a protocol approved by the NIH Animal Use Committee.
A left basolateral amygdala "chemitrode" was stereotactically implanted (anteroposterior Ϫ2.1 mm, lateral 4.2 mm, and dorsoventral Ϫ7.3 mm with respect to the amygdala) into each animal for infusion and depth EEG recording; a right amygdala electrode was implanted to obtain depth EEG recording alone. A screw electrode was placed in the skull over the right frontal cortex to obtain EEG recording with respect to a second screw electrode (as ground), which was placed over the left cerebellar cortex. Animals received injections of 1 g kainic acid into the left amygdala on the 1st day of the study. When the rats began to exhibit recurrent spontaneous seizure activity, we began to record EEG activity daily for 1 hour and continued this until the end of the study. The EEG signal was acquired at a sampling rate of 100 Hz by using a software-programmable 32-channel 
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Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy amplifier and appropriate software (Synamps amplifier and software; Neuroscan Labs, El Paso, TX). Epileptiform events identified by EEG activity were defined as voltage deflections that were greater in amplitude than seven times the prekainate mean rectified baseline EEG voltage and lasting at least 200 msec. Behavioral seizure activity was documented during the EEG recordings according to the five-stage Racine scoring system. 17 Two weeks after introduction of kainic acid and the appearance of spontaneous epileptiform activity, 10 g of ibotenate (concentration 2.5 mg/ml, vol 4 l) or vehicle (phosphate-buffered saline) was infused into the left amygdala by using a 32-gauge needle to create a lesion in the amygdala and surrounding structures, including the piriform cortex, endopiriform nucleus, and perirhinal cortex. Ibotenate was delivered at a rate of 0.1 l/minute to provide distribution through the extracellular space via convection. 2, [12] [13] [14] The animals were weighed during the course of the study on Days 0, 8, 14, 16, 22, and 36. The rats were killed on Day 36. Lesion distribution and electrode placement were later confirmed by a postmorten review of Nissl-stained coronal sections from paraffin-blocked brains.
We analyzed electrical epileptiform discharge data obtained on Days 8, 14, 22, and 36 after initial kainate introduction. Data obtained on Days 0 and 16 were omitted because it was thought that they might not reflect steady-state behavior of seizures before or after treatment with ibotenate (administered within 24 hours after the Day 14 epileptiform discharge data were measured). Thus, for each rat and each hemisphere, four seizure counts were measured. Two counts were obtained 8 and 14 days after kainate administration, but before injection of ibotenate or vehicle, and two counts were obtained after injection of ibotenate or vehicle on Days 22 and 36. For each rat and hemisphere, the number of events of Day 8 and Day 14 were averaged to obtain the pre-ibotenate/vehicle measurement and the number of events on Day 22 and Day 36 were averaged to obtain a post-ibotenate/vehicle value. These averages were computed for rats in both ibotenate-treated and vehicle-treated control groups. From these figures a percentage change between the pre-and posttreatment averages was computed for each rat. The use of a percentage change allows each rat to serve as its own control and partially adjusts for inherent variability within rats. A nonparametric, twosample permutation test of difference in means 7 was then applied to these percentage changes. This nonparametric approach was preferred to parametric models because fewer modeling assumptions are required, the procedure is less sensitive to outliers in data, and the method works well even in small samples.
Results
Only kainate-injected animals in which we documented spontaneous recurrent epileptiform events on the basis of EEG recordings and episodic behavioral seizures were studied. Twenty-four animals were injected with kainate. Three were eliminated from the study because of hardware failure. Five animals died from status epilepticus after kainate injection on the 1st day of the study. Ten (62.5%) of the remaining 16 rats displayed spontaneous recurrent epileptiform events. The electrical and behavioral manifestations of delayed seizures occurring after kainate injection were similar to those described previously. 1, 3 All rats included in the study exhibited bursts of high-frequency epileptiform activity, which were associated with transient behavioral arrest (tonic immobility). In addition, one third of the animals also exhibited prolonged 1-to 5-minute discharges that were associated invariably with Stage 3 or greater behavioral seizures (forelimb clonus, rearing, and falling). Epileptiform activity occurred sporadically during the first 2 weeks after kainate injection. By Day 15, the rate of occurrence of highvoltage spontaneous epileptiform events (defined in Materials and Methods) stabilized at a rate of two to three per second.
As illustrated in Fig. 1 left, ibotenate infusion into the left amygdala on Day 15 caused a sustained suppression in the mean frequency of spontaneous events recorded from the left amygdala electrode. There was no change in the mean frequency of events in animals that had been infused with vehicle. For the ipsilateral side the average percentage of reduction in epileptiform events after treatment was 85% (SD 11%) in the five rats in the ibotenate-treated group, where- as in the vehicle-treated group there was an average increase of 139% (SD 211%). Two rats in which there were increases of 434% and 242%, respectively, largely influenced the results in the vehicle-only group. The permutation test yielded a two-sided probability value of 0.016 for the hypothesis that there would be no difference in the percentage of reduction. Testing (again performed using permutation tests) of group differences in seizure counts on Days 8, 14, 22, and 36 yielded respective probability values of 0.79, 0.45, 0.02, and 0.07 for the hypothesis that there would be no difference in seizure counts between groups. The insignificance of the data obtained on Days 8 and 14 suggests that the two groups were similar before ibotenate administration.
Ibotenate infusion was also associated with a marked decrease in the frequency of events recorded from the contralateral amygdala electrode (Fig. 1 right) . The extent of the decrease, however, was less than that measured on the ipsilateral side The average percentage of reduction in epileptiform event counts after infusion was 72% in the ibotenate-treated group (SD 42%), whereas there was an average increase of 1% (SD 61%) in the vehicle-treated rats (p = 0.05 for percentage change). Tests of seizure counts on Days 8, 14, 22, and 36 yielded respective probability values of 0.79, 0.83, 0.24, and 0.59. The insignificance of findings on Days 22 and 36 may appear to contradict the overall significance shown with the percentage change test; however, the paradox is resolved by noting that post hoc tests are used to examine counts only at a fixed point in time, whereas the percentage change is used to consider effects over time within each rat. Although high pre-and posttreatment counts were measured in two ibotenate-treated rats, both showed a large percentage of reduction in the frequency of events. This pattern contributes to insignificant differences at a point in time, although there are significant differences in the percentage of change.
In addition to reducing the frequency of electrical epileptiform discharges, infusion of ibotenate also suppressed spontaneous behavioral seizure activity (Fig. 2) . There was a marked reduction in the frequency of behavioral arrests and seizures on the day following infusion in ibotenatetreated animals, but not in vehicle-treated control animals. The reduction in seizures persisted for the duration of the observation period. Thus, in the ibotenate-treated animals, the mean number of behavioral events during 1-hour recording sessions dropped from 5.2 Ϯ 1.2 on Day 14 (1 day before ibotenate infusion) to 1.2 Ϯ 0.9 on Day 36 (21 days after ibotenate infusion). In contrast, there was no significant change in the number of behavioral arrests and seizures in control animals that received vehicle infusions (4.8 Ϯ 1.1 on Day 14; 4.6 Ϯ 0.7 on Day 36).
Additional measures of the level of behavioral impairment in kainate-treated animals are weight and appearance. Animals in the vehicle-treated control group were emaciated for their ages, whereas those treated with ibotenate had normal weights for their ages. Figure 3 shows the mean weights of animals in the vehicle-and ibotenate-treated groups. Both groups maintained approximately equal weights during the time period before ibotenate infusion. Rats that received ibotenate, however, displayed significantly greater weights 3 weeks after infusion (ibotenate-treated group 501.4 Ϯ 24.2 g; vehicle-treated group 399.6 Ϯ 5.7 g; p Ͻ 0.01), indicating that increased seizure activity in the vehicle-treated animals was associated with failure to thrive. Other behavioral effects such as maze running ability or memory were not assessed.
In general, histological examination of specimens from animals infused with kainic acid and ibotenate showed a greater degree and a wider distribution of cell loss in the temporal lobe (particularly the piriform cortex) of the infused side than those in specimens from animals that received kainate alone. No attempt, however, was made to quantify the extent of cell loss contributed by kainate and ibotenate in the same region.
Discussion
These experiments demonstrate that a single intraamygdala infusion with the excitotoxin ibotenate can permanently obliterate a seizure focus induced by kainate, resulting in suppression of electrical and behavioral seizure activity. We hypothesize that the effects of ibotenate on seizure activity are caused by destruction of hyperexcitable neurons in the seizure focus. Chemical eradication of epileptic neurons suppresses abnormal firing at the focus site in the ipsilateral amygdala and also reduces spread of epileptic activity to distal sites, as demonstrated by diminished epileptiform activity in the contralateral amygdala and a reduction in behavioral seizure activity. Ibotenate is a neuron-specific cell toxin that creates axon-sparing lesions in part through activation of NMDA-type Ca ϩϩ -permeable ionotropic glutamate receptors. Nevertheless, ibotenate is a more potent cell toxin than NMDA itself, 10 possibly because of its additional actions on metabotropic glutamate receptors that can trigger intracellular Ca ϩϩ release. 15 Ibotenate is unique among excitatory amino acids in that it is not epileptogenic. 5, 16, 20 Although the precise differences between ibotenate and other excitatory amino acids that account for this lack of epileptogenic activity are not known with certainty, it has been noted that ibotenate undergoes enzyme-catalyzed decarboxylation to the primary amine muscimol. 10 The resulting muscimol, a potent ␥-aminobutyric acid A receptor agonist, could limit the magnitude and spread of excitation produced by ibotenate. In any case, our studies confirm that large doses of ibotenate can be infused into limbic structures of the rat brain without causing seizures or death.
Convection-Enhanced Delivery
Many neurological disorders, including epilepsy, might be best treated by selective inhibition or augmentation of neuronal circuits. Although a number of effective therapeutic compounds exist for treating such pathological disorders in small animal models, the clinical use of these agents has not been possible because of the inability to deliver them in a selective and homogeneous manner in clinically significant volumes to the CNS by using conventional delivery methods. Specifically, the systemic delivery of therapeutic compounds to the CNS is not anatomically selective, is limited by the blood-brain barrier, and may be associated with systemic toxicity. Regional methods for CNS drug delivery include intraventricular infusion and implanted polymers. Because both these techniques rely on diffusion for dispersal of therapeutic molecules within neural parenchyma, distribution is heterogeneous and is limited to clinically insignificant volumes by molecular weight, concentration, size, and diffusivity of the therapeutic agent.
To overcome the problems associated with available methods of conventional drug delivery, we previously investigated the use of convection for the selective distribution of molecules within the CNS. 2, [12] [13] [14] Because convection-enhanced delivery distributes molecules directly into the parenchyma, it avoids the blood-brain barrier and can be used to deliver infusate directly into targeted regions of the CNS. Because convective delivery does not depend on diffusive forces for drug distribution, it permits distribution of various molecules in clinically significant volumes within the brain and does so with relative independence of the molecular weight, size, concentration, and diffusivity of the particular therapeutic agent. 2, [12] [13] [14] Moreover, the "squarewave" distribution pattern afforded by convection-enhanced delivery allows for precise homogeneous delivery of the desired infusate concentration to specific brain regions. 2, [12] [13] [14] Because of the unique properties of convection-enhanced delivery, its use in the excitotoxic ablation of selected brain regions for the treatment of medically intractable epilepsy may have benefits over conventional surgical treatment techniques. First, because ibotenate lesioning is specific to neurons and spares white matter, inadvertent damage to surrounding white matter tracts can be avoided. Second, the arrest of seizure activity in this model of epilepsy appears to be predicated only on the selective destruction of neuronal perikarya and not on the damage or interruption of white matter tracts in the resection region. This suggests that only the selective destruction of neurons is necessary to affect a successful outcome. Therefore, it may be possible to eliminate the need for extensive anatomical resection and its attendant risks. Third, in this animal study the ibotenateinduced lesions were less extensive than the corresponding regions that are resected during temporal lobectomy performed in humans. Ibotenate infusions created lesions in the amygdala and surrounding structures, including the piriform cortex, endopiriform nucleus, and perirhinal cortex. These structures are confined within the parahippocampal gyrus of the human brain. Human temporal lobe resections typically involve various combinations of lateral structures (superior, middle, and inferior temporal gyri) and mesiobasal structures (hippocampus, parahippocampal gyrus, and amygdala). Thus, the new approach described here eliminates the destruction of the lateral temporal neocortex to achieve obliteration of an epileptic focus within mesiobasal temporal lobe structures or surrounding white matter. Fourth, convection-enhanced delivery provides certain unique opportunities to enhance the safety and efficacy of surgical procedures that are not available with the use of conventional resective techniques. For example, convection-enhanced delivery of surrogate tracers that can be imaged with computerized tomography or magnetic resonance imaging could be used to define the extent of the expected lesion precisely before final ablation (Nguyen, et al., and Lonser, et al., unpublished data). Similarly, infusion with reversible inhibitors of neuronal activity, such as local anesthetic agents or ␥-aminobutyric acid A receptor agonists (such as muscimol) might permit the surgeon to verify the functional effects of the expected lesion.
Conclusions
The present results indicate that targeted local delivery of neuron-specific neurotoxins may be an alternative to resective neurosurgery in the treatment of localization-related epilepsies. Because the basis of human focal epilepsies at present is poorly understood, however, it remains to be determined whether an approach that is successful in ameliorating an induced epileptogenic focus in an animal model can also be of use in the treatment of the spontaneously arising foci underlying partial seizure disorders in humans.
